haloperidol has been researched along with Developmental Disabilities in 3 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The methionine-folate cycle-dependent one-carbon metabolism is implicated in the pathophysiology of schizophrenia." | 3.88 | Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits. ( Abbott, GW; Alachkar, A; Civelli, O; Hamzeh, AR; Lee, SM; Sanathara, N; Wang, L; Wang, Z; Xu, X; Yoshimura, R, 2018) |
| "We summarise preliminary findings from our ongoing magnetic resonance imaging and spectroscopy studies of first-episode schizophrenia patients being conducted prospectively from index evaluations through a period of two years; during this period, patients were treated with either a conventional antipsychotic such as haloperidol, or the atypical risperidone." | 3.70 | Research and treatment strategies in first-episode psychoses. The Pittsburgh experience. ( Haas, GL; Keshavan, MS; Pettegrew, JW; Schooler, NR; Sweeney, JA, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alachkar, A | 1 |
| Wang, L | 1 |
| Yoshimura, R | 1 |
| Hamzeh, AR | 1 |
| Wang, Z | 1 |
| Sanathara, N | 1 |
| Lee, SM | 1 |
| Xu, X | 1 |
| Abbott, GW | 1 |
| Civelli, O | 1 |
| Keshavan, MS | 1 |
| Schooler, NR | 1 |
| Sweeney, JA | 1 |
| Haas, GL | 1 |
| Pettegrew, JW | 1 |
| Lienert, GA | 1 |
| Bergman, LR | 1 |
3 other studies available for haloperidol and Developmental Disabilities
| Article | Year |
|---|---|
Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits.
Topics: Animals; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; CA1 Region, Hippocampal | 2018 |
Research and treatment strategies in first-episode psychoses. The Pittsburgh experience.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain Diseases; Developmental Disabilities; Episode of Care | 1998 |
Longisectional interaction structure analysis (LISA) in psychopharmacology and developmental psychopathology.
Topics: Adolescent; Child; Developmental Disabilities; Drug Evaluation; Haloperidol; Humans; Longitudinal St | 1985 |